Company Monitoring Page for MorphoSys

latest headlines for company on cafepharma

Morphosys to buy Constellation in $1.7B deal, aided by unusual funding
BioPharma Dive
Wed, 06/2/21 - 12:10 pm
Tags:
MorphoSys, M&A, Constellation Pharmaceuticals
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
Tue, 09/22/20 - 10:15 pm
Tags:
FDA, Kite Pharma, Tecartus, Novartis, Kesimpta, MorphoSys, Monjuvi, OptumRx
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
Mon, 08/3/20 - 10:14 am
Tags:
FDA, Monjuvi, CAR-T, MorphoSys, Incyte, diffuse large B-cell lymphoma
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
Mon, 03/2/20 - 09:37 am
Tags:
MorphoSys, Gilead Sciences, Novartis, CAR-T, tafasitamab, DLBCL
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Mon, 01/13/20 - 11:51 pm
Tags:
Incyte, MorphoSys, lymphoma, tafasitamab
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Fierce Biotech
Tue, 10/29/19 - 09:57 am
Tags:
MorphoSys, Galapagos, Novartis, MOR106, atopic dermatitis, Dupixent, Sanofi
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 06/16/19 - 05:41 pm
Tags:
FDA, Merck, Arqule, Affimed, BeiGene, Epizyme, MorphoSys, Theravance, Allena Pharma, Akero Therapeutics, Atreca, Dermavant Sciences, Personalis, Prevail Therapeutics, Stoke Therapeutics, IPOs
Morphosys to take on CAR-Ts in NHL with promising antibody
Pharmaforum
Mon, 05/20/19 - 11:02 pm
Tags:
MorphoSys, Celgene, Revlimid, non-Hodgkin lymphoma, clinical trials, tafasitamab
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Endpoints
Fri, 05/17/19 - 01:03 pm
Tags:
CAR-T, MorphoSys, Novartis, Gilead Sciences, tafasitamab, DLBCL
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
CP Wire
Fri, 02/1/19 - 09:44 am
Tags:
MorphoSys, Janssen, Genmab, daratumumab, patents
Fri, 02/1/19 - 09:25 am
Tags:
MorphoSys, Janssen, Genmab, patent lawsuits, patents, Darazalex
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
CP Wire
Mon, 01/28/19 - 11:02 am
Tags:
MorphoSys, Janssen, Genmab, patents
Mon, 01/28/19 - 10:10 am
Tags:
MorphoSys, Janssen, Genmab
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
Tags:
clinical trials, Alzheimer's disease, Biogen, Duchenne Muscular Dystrophy, Pfizer, Solid Biosciences, Sarepta Therapeutics, hemophilia A, Biomarin, Multiple Myeloma, Celgene, Bluebird Bio, Amgen, solid tumors, Bristol-Myers Squibb, Nektar Therapeutics, age-related macular degeneration, Regenxbio, SAGE Therapeutics, MorphoSys
With no partner, MorphoSys drops MOR202 in myeloma
Biopharma Dive
Fri, 08/3/18 - 10:53 pm
Tags:
MorphoSys, earnings, anti-CD3 antibody, MOR202
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Yahoo/Bloomberg
Thu, 07/19/18 - 09:53 am
Tags:
Novartis, Galapagos, MorphoSys, MOR106, atopic dermatitis
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
Wed, 07/11/18 - 11:35 am
Tags:
JNJ, Tremfya, MorphoSys, Janssen, Crohn's Disease, clinical trials
In knockout IPO offerings, MorphoSys and Surface Oncology haul combined $316M in upsized deals
Endpoints
Fri, 04/20/18 - 09:46 am
Tags:
IPOs, MorphoSys, Surface Oncology, NASDAQ
Galapagos peaks as AbbVie hype builds, Shorts target Bavarian, MorphoSys makes GPCR play
Fierce Biotech
Fri, 08/7/15 - 10:44 am
Tags:
Galapagos, AbbVie, Bavarian Nordic, Intec Pharma, MorphoSys
MorphoSys: That Celgene-abandoned cancer drug isn't dead yet
Fierce Biotech
Mon, 04/6/15 - 11:03 am
Tags:
MorphoSys, Celgene, MOR202

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.